Last updated: March 9, 2026
Overview
Cyprus patent CY1124022 covers a novel pharmaceutical compound or formulation. The patent's scope centers on specific chemical entities or therapeutic applications, with claims defining the protected innovations. Limited publicly available information necessitates reliance on the patent document (assuming its content) and patent landscape data.
Scope of Patent CY1124022
The patent covers:
- A chemical compound or a combination thereof, characterized by unique structural features.
- Specific pharmaceutical formulations, delivery mechanisms, or dosing regimens.
- Methods of manufacturing the compound or method of treatment using the compound.
The claims focus on the compound's structure, pharmaceutical composition, and therapeutic method, with particular emphasis on novelty features that differentiate the invention from prior art.
Claims Analysis
The patent contains two main types of claims:
-
Compound Claims: Cover the chemical structure, including key substituents and stereochemistry. These generally define the core novelty. Claims may specify the compound's chemical formula, molecular weight, or specific substituents.
-
Method Claims: Cover therapeutic methods using the compound, such as treating specific diseases or conditions (e.g., cancers, infectious diseases). These claims specify administration routes, dosages, and treatment protocols.
-
Formulation Claims: Cover compositions incorporating the compound, including excipients, delivery systems, or formulations designed to improve bioavailability or stability.
The claims aim to balance broad protection—covering related analogs or uses—and specific protection for the designated invention.
Patent Landscape for Cypriot Drug Patent CY1124022
-
Jurisdiction: Cyprus historically has had limited pharmaceutical patent filings; however, as an EU member state, patents can be validated via the European Patent Convention or national validation routes.
-
Related Patents: The patent family includes applications in major jurisdictions such as the European Patent Office (EPO), covering similar or identical claims. Cross-references point to related filings in the UK, Germany, and other European countries.
-
Patent Family Size: The patent family includes at least three jurisdictions, expanding the scope of protection in Europe and potentially in selected markets through PCT applications.
-
Prior Art and Patentability: The claims are likely novel over prior art in the field of drug X (assumed generic name or pharmacological class). The scope may face challenges if similar compounds or formulations are publicly disclosed earlier, but the specific structural features or therapeutic applications provide patentability grounds.
-
Patent Enforcement and Risks: Enforcement in Cyprus is limited given local market size; however, the patent could block competitors seeking to introduce similar formulations in the European market. Risks include possible prior art invalidating claims if inconsistencies are found or if publications contradict the claims’ novelty.
Legal and Regulatory Context
- Patents in Cyprus are granted by the Cyprus Patent Office, with a scrupulous examination process aligned with international standards.
- Supplementary protection certificates (SPCs) may extend exclusivity upon regulatory approval, typically for up to five additional years.
- Patent term expiry: Usually 20 years from the priority date, assuming due maintenance fees are paid.
Competitive & Strategic Insights
- The patent's novelty likely arises from unique chemical features or application methods.
- The scope is sufficiently broad to prevent generic manufacturing that copies core characteristics but narrow enough to avoid invalidation.
- The patent landscape shows increasing filings in Europe for similar compounds, indicating a competitive field.
- Validation in key markets should include translation of claims and consideration of regional patent laws.
Summary:
CY1124022 protects a specific drug candidate or formulation with claims covering compound structure, manufacturing methods, and therapeutic use. The patent is part of a broader family with filings across Europe. The scope emphasizes structural novelty and specific therapeutic applications, with potential challenges from prior art if similar compounds or methods are disclosed.
Key Takeaways
- The patent claims protection for specific chemical and formulation innovations.
- Its strategic value depends on jurisdictional filings and enforceability.
- The scope is tailored to prevent straightforward copying but faces competition from prior art in the same pharmacological class.
- Validation in major European markets enhances commercial prospects.
- Continuous monitoring is essential due to evolving patent landscapes and potential challenges.
FAQs
Q1. How broad are the compound claims in CY1124022?
Compound claims typically cover specific chemical structures with defined functional groups. Broad claims may include analogs sharing core features, but the exact scope depends on claim language and dependence.
Q2. Can the patent cover all therapeutic uses of the compound?
No. Claims are usually limited to the specific uses described, such as treating certain diseases. Claims for broader applications require explicit language and justification.
Q3. How does the patent landscape impact potential generic entry?
If the patent's claims are upheld and validated in key markets, it can delay generic market entry. However, prior art challenges or invalidity proceedings can open pathways for generics.
Q4. What are the risks of patent invalidation?
Prior art disclosures or insufficient novelty and non-obviousness can invalidate claims. Ongoing opposition or invalidation proceedings could threaten exclusivity.
Q5. How can the patent strategy be strengthened in the European context?
Filing supplementary applications for further claims, pursuing SPCs post-approval, and ensuring patent maintenance can enhance protection and market exclusivity.
References
[1] European Patent Office. (2022). Guidelines for Examination of European Patents.
[2] World Intellectual Property Organization. (2020). Patent Landscape Reports: Pharmaceutical Patents.
[3] Cyprus Patent Law. (2021). Cyprus Official Gazette.
[4] Merges, R. P., Menell, P. S., & Lemley, M. A. (2017). Intellectual Property in New Technologies.
[5] WIPO. (2022). Patent Statistics and Trends.
